Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. Poeppel TD, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29234845 Free article.
Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.
Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K. Zettinig G, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1224-30. doi: 10.1007/s00259-004-1575-0. Epub 2004 Jun 10. Eur J Nucl Med Mol Imaging. 2004. PMID: 15197504 Clinical Trial.
11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K. Wachter S, et al. Among authors: mitterhauser m. J Clin Oncol. 2006 Jun 1;24(16):2513-9. doi: 10.1200/JCO.2005.03.5279. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636343
[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents.
Haeusler D, Kuntner C, Nics L, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Wadsak W, Hacker M, Mitterhauser M. Haeusler D, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):741-9. doi: 10.1007/s00259-014-2976-3. Epub 2015 Jan 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25601336 Free PMC article.
Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor.
Haeusler D, Grassinger L, Fuchshuber F, Hörleinsberger WJ, Höftberger R, Leisser I, Girschele F, Shanab K, Spreitzer H, Gerdenitsch W, Hacker M, Wadsak W, Mitterhauser M. Haeusler D, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2015 May;42(6):928-39. doi: 10.1007/s00259-014-2985-2. Epub 2015 Mar 5. Eur J Nucl Med Mol Imaging. 2015. PMID: 25739834 Free PMC article.
[Therapy of bone metastases with radium-223. German guidelines].
Pöppel TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M. Pöppel TD, et al. Among authors: mitterhauser m. Nuklearmedizin. 2016 Sep 26;55(5):177-86. doi: 10.3413/Nukmed-2016050001. Epub 2016 Jul 15. Nuklearmedizin. 2016. PMID: 27417067 German.
The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.
Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M. Li S, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1732-1741. doi: 10.1007/s00259-017-3724-2. Epub 2017 May 29. Eur J Nucl Med Mol Imaging. 2017. PMID: 28555333 Free PMC article.
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Grubmüller B, et al. Among authors: mitterhauser m. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. Prostate. 2020. PMID: 31614001
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.
Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Rasul S, et al. Among authors: mitterhauser m. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):713-720. doi: 10.1007/s00259-019-04584-1. Epub 2019 Nov 28. Eur J Nucl Med Mol Imaging. 2020. PMID: 31781834 Free PMC article.
242 results